Home › Compare › LPTX vs EQR

LPTX vs EQR: Dividend Comparison 2026

LPTX yields 304.60% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 LPTX wins by $1677.45M in total portfolio value
10 years
LPTX
LPTX
● Live price
304.60%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1677.50M
Annual income
$1,019,249,502.55
Full LPTX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — LPTX vs EQR

📍 LPTX pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLPTXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LPTX + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
LPTX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LPTX
Annual income on $10K today (after 15% tax)
$25,890.95/yr
After 10yr DRIP, annual income (after tax)
$866,362,077.17/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, LPTX beats the other by $866,357,422.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LPTX + EQR for your $10,000?

LPTX: 50%EQR: 50%
100% EQR50/50100% LPTX
Portfolio after 10yr
$838.77M
Annual income
$509,627,489.08/yr
Blended yield
60.76%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

LPTX
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Price Target
$5.50
+737.6% upside vs current
Range: $5.50 — $5.50
Altman Z
-1.9
Piotroski
4/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LPTX buys
0
EQR buys
0
No recent congressional trades found for LPTX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLPTXEQR
Forward yield304.60% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$1677.50M ✓$47.8K
Annual income after 10y$1,019,249,502.55 ✓$5,475.61
Total dividends collected$1611.81M ✓$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$5.50$70.35 ✓

Year-by-year: LPTX vs EQR ($10,000, DRIP)

YearLPTX PortfolioLPTX Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$41,160$30,459.95$11,380$679.82+$29.8K → LPTX
2$161,212$117,171.00$13,014$837.25+$148.2K → LPTX
3$601,400$428,903.22$14,961$1,036.20+$586.4K → LPTX
4$2,138,843$1,495,344.84$17,297$1,289.22+$2.12M → LPTX
5$7,258,751$4,970,189.23$20,121$1,613.15+$7.24M → LPTX
6$23,531,071$15,764,207.60$23,561$2,030.84+$23.51M → LPTX
7$72,938,668$47,760,421.89$27,783$2,573.54+$72.91M → LPTX
8$216,401,174$138,356,798.39$33,013$3,284.39+$216.37M → LPTX
9$615,184,508$383,635,252.06$39,547$4,223.51+$615.14M → LPTX
10$1,677,496,926$1,019,249,502.55$47,791$5,475.61+$1677.45M → LPTX

LPTX vs EQR: Complete Analysis 2026

LPTX — Stock

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Full LPTX Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this LPTX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LPTX vs SCHDLPTX vs JEPILPTX vs OLPTX vs KOLPTX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.